Michael E. Saunders
Profile
Michael E.
Saunders has been Vice President of Clinical Development for Allos Therapeutics, Inc. since November 2004.
Previously, he was Senior Medical Director of Allos Therapeutics from December 2003 to October 2004.
Dr. Saunders was Medical Director of Baxter Hemoglobin Therapeutics, Global Medical Director of BioSurgery and Pharmacovigilance for Baxter BioScience, Senior Director of Clinical Research for Somatogen, Senior Director of Clinical Research and Cardiovascular for Searle and Director of Clinical Research and Cardiovascular for Rhone-Poulenc Rorer.
He received an MD from the University of Kansas School of Medicine.
Former positions of Michael E. Saunders
| Companies | Position | End |
|---|---|---|
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Chief Tech/Sci/R&D Officer | - |
Training of Michael E. Saunders
| University of Kansas | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 1 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
- Stock Market
- Insiders
- Michael E. Saunders
